TALZENNA (talazoparib)
TherapyPfizer
TALZENNA (talazoparib) from Pfizer is a PARP inhibitor used in germline BRCA-mutated cancers.
Approvals
1
Indications
1
Biomarkers
2
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TALZENNA. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where TALZENNA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Breast Cancer Solid Tumor · Breast | BRCA1
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TALZENNA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TALZENNA for eligible patients.
Test
BRACAnalysis CDx
Myriad Genetics
Method
PCR
Specimen
Whole blood
1 approvalView test profile →